WO2021023204A1 - Use of cdk4/6 inhibitor in combination with multi-target tyrosine kinase inhibitor in preparing medicament for treating tumor - Google Patents

Abstract

Disclosed is a use of a CDK4/6 inhibitor in combination with a multi-target tyrosine kinase inhibitor in preparing a medicament for treating a tumor. Specifically, the CDK4/6 inhibitor is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and the multi-target tyrosine kinase inhibitor is a compound represented by formula (II) or a pharmaceutically acceptable salt thereof.

Description

Application of CDK4/6 inhibitor and multi-target tyrosine kinase inhibitor in preparing medicine for treating tumor

This application claims the priority of the Chinese patent application CN201910720522.1 whose filing date is August 6, 2019. This application quotes the full text of the aforementioned Chinese patent application.

Technical field

The application relates to the use of a combination of a CDK4/6 inhibitor and a multi-target tyrosine kinase inhibitor in the preparation of a drug for treating tumors.

Background technique

Breast cancer is one of the most common malignant tumors in women. There are approximately 1.3 million new cases worldwide each year. In my country, the incidence of breast cancer accounts for 7%-10% of the incidence of various malignant tumors throughout the body, and about 18% of all female tumors. At present, the number of patients in China has exceeded 500,000, and its incidence is increasing rapidly in some large cities. It has been ranked first in the spectrum of female tumor incidence, and nearly 50% of patients have recurrence and metastasis after treatment. In recent years, with the deepening of tumor molecular biology research, molecular targeted therapy has become more and more widely used in the treatment of breast cancer and has achieved more significant curative effects. It has become the first after the three traditional modes of surgery, radiotherapy and chemotherapy. This new treatment model is also a hot spot in the field of breast cancer treatment.

Cyclin-dependent kinase (Cyclin-dependent kinase, CDK) is a type of serine/threonine kinase that forms a dimer with the corresponding cyclin (Cyclin), and then phosphorylates downstream protein molecules to promote the cell cycle Orderly progress in each phase to achieve cell growth and proliferation. At present, a variety of CDK4/6 selective inhibitors are in clinical trials or have been approved for listing in foreign countries, including Pfizer’s Palbociclib, Novartis’s Ribociclib and Eli Lilly’s Abemaciclib.

WO2014183520 discloses a chemical named 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperidin-4-yl)pyridin-2-yl)amino)pyrido[2 ,3-d]pyrimidin-7(8H)-one, the structural formula is as the CDK4/6 inhibitor shown in formula (I), which has significant CDK4/6 inhibitory activity and high selectivity,

WO2016124067A discloses the isethionate of the compound represented by the above formula (I) and a preparation method thereof.

There have been many studies on the combination of CDK4/6 inhibitors and other drugs. WO2017193141A discloses that the combination of CDK4/6 inhibitors and EGFR inhibitors can be used to treat triple-negative breast cancer; WO2016024232A discloses CDK4/6 inhibitors and BTK kinase Combination of inhibitors to treat cancer; Lori S. Hart et al. found that CDK4/6 inhibitors and MEK inhibitors were used in neuroblastoma before clinical use in "Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma" Tumor has a synergistic effect; CN103781480A discloses that the combination of CDK4/6 inhibitor and FGFR kinase inhibitor can be used to treat cancer; J. Bollard et al. "Palbociclib(PD-0332991)a selective CDK4/6 inhibitor, restricts tumor growth in preclinical models of hepatocellular Carcinoma" discloses that Palbociclib alone or in combination with sorafenib may become a new strategy for the treatment of hepatocellular carcinoma; CN106029097A discloses that the combination of abemaciclib and ramucirumab can be used to treat non-small cell lung cancer; CN108883182A discloses abemaciclib and ramulu The combination of monoclonal antibodies can be used to treat mantle cell lymphoma; WO2013006368A discloses that the combination of a CDK4/6 inhibitor and an FGFR kinase inhibitor has a synergistic effect on the growth of breast cancer cells.

The anti-tumor mechanism of TKIs may be achieved through the following ways: inhibiting the damage and repair of tumor cells, blocking cell division in G1 phase, inducing and maintaining cell apoptosis, and anti-angiogenesis. Overexpression of EGFR often indicates poor prognosis, fast metastasis, resistance to chemotherapy drugs, hormone resistance, and shorter survival time. The FDA has approved a variety of multi-target TKIs, such as: sorafenib (sorafenib), vandetanib (vandetanib) and Sunitinib (Sutent, SU-11248). WO2007085188 discloses a compound similar to Sunitinib, as shown in the following formula (II), which may be better applied to the treatment of the above-mentioned tumors. The chemical name of the compound is 5-(2-diethylamino-ethyl)-2-(5-fluoro-2-oxo-1,2-dihydro-indole-3-ylidene-methyl)- 3-Methyl-1,5,6,7-tetrahydro-pyrrole [3,2-c]pyridin-4-one, which is known to inhibit tumor proliferation and angiogenesis, and can selectively inhibit vascular endothelial growth factor The kinase activity of (VEGF) receptors can be used clinically for the treatment of renal cancer, gastrointestinal stromal tumors, colorectal cancer and pancreatic neuroendocrine tumors.

At present, there are few studies on the use of CDK4/6 inhibitors and amino kinase inhibitors in the treatment of breast cancer.

Summary of the invention

The application provides a use of a combination of a CDK4/6 inhibitor and a multi-target tyrosine kinase inhibitor in the preparation of drugs for treating tumors.

The multi-target tyrosine kinase inhibitor described in this application may refer to a compound that can simultaneously inhibit targets such as VEGFR, EGFR, and Her-2.

The CDK4/6 inhibitor described in this application can be a compound represented by formula (I) or a pharmaceutically acceptable salt thereof,

In the present application, the pharmaceutically acceptable salt of the compound represented by formula (I) may be selected from hydrochloride, phosphate, hydrogen phosphate, sulfate, hydrogen sulfate, sulfite, acetate, oxalate, propylene Diacid salt, valerate, glutamate, oleate, palmitate, stearate, laurate, borate, p-toluenesulfonate, methanesulfonate, isethionate Salt, maleate, malate, tartrate, benzoate, pamoate, salicylate, vanillate, mandelate, succinate, gluconate, lactobionate or Lauryl sulfonate is preferably isethionate.

In an alternative embodiment, the multi-target tyrosine kinase inhibitor may be a compound represented by formula (II) or a pharmaceutically acceptable salt thereof,

In an alternative embodiment, the pharmaceutically acceptable salt of the compound represented by formula (II) is malate.

The tumor described in this application can be selected from sarcoma, lymphoma, lung cancer, bronchial cancer, prostate cancer, pancreatic cancer, gastrointestinal cancer, colon cancer, rectal cancer, colorectal adenoma, thyroid cancer, liver cancer, intrahepatic cholangiocarcinoma , Hepatocellular carcinoma, adrenal carcinoma, stomach cancer, stomach tumor, glioma, glioblastoma, endometrial cancer, melanoma, kidney cancer, renal pelvis cancer, bladder cancer, uterine body cancer, cervical cancer, vaginal cancer , Ovarian cancer, multiple myeloma, esophageal cancer, leukemia, acute myeloid leukemia, chronic myeloid leukemia, lymphocytic leukemia, myeloid leukemia, brain tumors, brain cancer, oral and pharynx cancer, laryngeal cancer, Small bowel cancer, non-Hodgkin's lymphoma, melanoma, colon chorioaldenoma, neoplasm, epithelial cancer, breast cancer, basal cell carcinoma, squamous cell carcinoma, actinic keratosis, tumor, neck or head Tumors, primary thrombocytosis, myeloid metaplastic myelofibrosis and macroglobulinemia, preferably breast cancer, hepatocellular carcinoma, colon cancer.

In an alternative embodiment, the breast cancer is hormone receptor positive breast cancer.

In an alternative embodiment, the breast cancer is triple negative breast cancer.

In an alternative embodiment, the breast cancer is her2 positive breast cancer.

In an optional embodiment, the dosage of the CDK4/6 inhibitor is selected from 1-500 mg, preferably 25-200 mg, more preferably 100-150 mg, and the frequency of administration may be once a day or twice a day, preferably Once a day.

In an alternative embodiment, the dosage of the CDK4/6 inhibitor is 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, preferably 100 mg, 125 mg, or 150 mg, and the frequency of administration can be once a day or a day. Twice, preferably once a day.

In an optional embodiment, the dose of the multi-target tyrosine kinase inhibitor is selected from 0.1-1000 mg, and the frequency of administration may be once a day, twice a day, or three times a day, preferably once a day.

In an optional embodiment, the dose of the multi-target tyrosine kinase inhibitor is selected from 0.1-100 mg, specifically 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8mg, 0.9mg, 1.0mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg, 10mg, 11mg, 12mg, 13mg, 14mg, 15mg, 16mg, 17mg, 18mg, 19mg, 20mg, 21mg, 22mg , 23mg, 24mg, 25mg, 26mg, 27mg, 28mg, 29mg, 30mg, 31mg, 32mg, 33mg, 34mg, 35mg, 36mg, 37mg, 38mg, 39mg, 40mg, 41mg, 42mg, 43mg, 44mg, 45mg, 46mg, 47mg , 48mg, 49mg, 50mg, 51mg, 52mg, 53mg, 54mg, 55mg, 56mg, 57mg, 58mg, 59mg, 60mg, 61mg, 62mg, 63mg, 64mg, 65mg, 66mg, 67mg, 68mg, 69mg, 70mg, 71mg, 72mg , 73mg, 74mg, 75mg, 76mg, 77mg, 78mg, 79mg, 80mg, 81mg, 82mg, 83mg, 84mg, 85mg, 86mg, 87mg, 88mg, 89mg, 90mg, 91mg, 92mg, 93mg, 94mg, 95mg, 96mg, 97mg , 98mg, 99mg, 100mg, the frequency of administration can be once a day, twice a day, or three times a day, preferably once a day.

In an optional embodiment of the present application, the multi-target tyrosine kinase inhibitor is administered according to body weight, and the dose can be selected from 0.1-10.0 mg/kg.

In the above regimen of administration according to body weight, the dose of the multi-target tyrosine kinase inhibitor may be 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg, 0.6mg/kg, 0.7mg/kg, 0.8mg/kg, 0.9mg/kg, 1.0mg/kg, 1.2mg/kg, 1.4mg/kg, 1.6mg/kg, 1.8mg/kg, 2.0mg/kg, 2.2mg/kg, 2.4mg/kg, 2.6mg/kg, 2.8mg/kg, 3.0mg/kg, 3.2mg/kg, 3.4mg/kg, 3.6mg/kg, 3.8mg/kg, 4.0mg/kg, 4.2mg/kg, 4.4mg/kg, 4.6mg/kg, 4.8mg/kg, 5.0mg/kg, 5.2mg/kg, 5.4mg/kg, 5.6mg/kg, 5.8mg/kg, 6.0mg/kg, 6.2mg/kg, 6.4mg/kg, 6.6mg/kg, 6.8mg/kg, 7.0mg/kg, 7.2mg/kg, 7.4mg/kg, 7.6mg/kg, 7.8mg/kg, 8.0mg/kg, 8.2mg/kg, 8.4mg/kg, 8.6mg/kg, 8.8mg/kg, 9.0mg/kg, 9.2mg/kg, 9.4mg/kg, 9.6mg/kg, 9.8mg/kg, 10.0mg/kg, The frequency of administration may be once a day, twice a day, or three times a day, preferably once a day.

In an optional embodiment, the dose of the multi-target tyrosine kinase inhibitor is selected from 1-25 mg, specifically 15 mg, 20 mg, 25 mg, and the frequency of administration can be once a day, twice a day, or once a day. Three times, preferably once a day.

In an optional embodiment, the dosage of the CDK4/6 inhibitor is selected from 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, and the frequency of administration can be once a day, twice a day, Three times, the dose of the multi-target tyrosine kinase inhibitor is selected from 0.1-100 mg, and the frequency of administration may be once a day, twice a day, or three times a day.

In an optional embodiment, the dosage of the CDK4/6 inhibitor is selected from 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, and the frequency of administration can be once a day, twice a day, Three times, the dose of the multi-target tyrosine kinase inhibitor is selected from 1-25 mg, and the frequency of administration can be once a day, twice a day, or three times a day.

In an optional embodiment, the dose of the CDK4/6 inhibitor is selected from 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, and the frequency of administration is once a day. The multi-target tyrosine The dose of kinase inhibitor is selected from 15mg, 20mg, 25mg, and the frequency of administration is once a day.

In an optional embodiment, the dosage of the CDK4/6 inhibitor is 100 mg, and the frequency of administration is once a day, and the dosage of the multi-target tyrosine kinase inhibitor is selected from 15 mg, 20 mg, 25 mg, The frequency of administration is once a day.

In an optional embodiment, the dosage of the CDK4/6 inhibitor is 125 mg, and the frequency of administration is once a day, and the dosage of the multi-target tyrosine kinase inhibitor is selected from 15 mg, 20 mg, and 25 mg, The frequency of administration is once a day.

In an optional embodiment, the dosage of the CDK4/6 inhibitor is 150 mg, and the frequency of administration is once a day, and the dosage of the multi-target tyrosine kinase inhibitor is selected from 15 mg, 20 mg, 25 mg, The frequency of administration is once a day.

In an optional embodiment, the dosage of the CDK4/6 inhibitor is 175 mg, and the frequency of administration is once a day, and the dosage of the multi-target tyrosine kinase inhibitor is selected from 15 mg, 20 mg, 25 mg, The frequency of administration is once a day.

In an optional embodiment, the dose of the CDK4/6 inhibitor is selected from 100 mg, 125 mg, 150 mg, and 175 mg, the frequency of administration is once a day, and the dose of the multi-target tyrosine kinase inhibitor is 15mg, the frequency of administration is once a day.

In an optional embodiment, the dose of the CDK4/6 inhibitor is selected from 100 mg, 125 mg, 150 mg, and 175 mg, the frequency of administration is once a day, and the dose of the multi-target tyrosine kinase inhibitor is 20mg, the frequency of administration is once a day.

In an optional embodiment, the dose of the CDK4/6 inhibitor is selected from 100 mg, 125 mg, 150 mg, and 175 mg, the frequency of administration is once a day, and the dose of the multi-target tyrosine kinase inhibitor is 25mg, the frequency of administration is once a day.

The route of the combination described in this application includes, but is not limited to, oral administration, parenteral administration, and transdermal administration. The parenteral administration includes but is not limited to intravenous injection, subcutaneous injection, and intramuscular injection.

This application provides a method for treating tumors, which includes administering to a patient a therapeutically effective amount of the above-mentioned CDK4/6 inhibitor and a multi-target tyrosine kinase inhibitor.

This application provides a pharmaceutical composition comprising the above-mentioned CDK4/6 inhibitor, a multi-target tyrosine kinase inhibitor and one or more pharmaceutically acceptable excipients, diluents or carriers.

The “combination” mentioned in this application is a mode of administration, which means that at least one dose of CDK4/6 inhibitor and multi-target tyrosine kinase inhibitor is administered within a certain period of time, in which both drugs Show pharmacological effects. The time limit may be within one administration cycle, preferably within 4 weeks, within 3 weeks, within 2 weeks, within 1 week, or within 24 hours. CDK4/6 inhibitors and multi-target tyrosine kinase inhibitors can be administered simultaneously or in no particular order. This period includes treatments in which CDK4/6 inhibitors, multi-target tyrosine kinase inhibitors are administered through the same route of administration or different routes of administration.

Description of the drawings

Figure 1. Body weight change of xxT47D xenograft tumor model tumor-bearing mice after administration of test substance;

Figure 2. The relative weight change of the xxT47D xenograft tumor model tumor-bearing mice after administration of the test substance;

Figure 3. Growth curves of tumors in each group.

detailed description

The following examples are used to further describe the application, but these examples do not limit the scope of the application.

Example 1. Compound isethionate (drug A) of formula (I) as a single agent or combined with compound malate of formula (II) (drug B) in xxT47D human breast cancer cells (ER+, HER2 -) In vivo pharmacodynamics study on BALB/c nude mouse model of subcutaneous xenograft tumor

1. Experimental materials

Drug A is prepared according to the method disclosed in WO2016124067A;

Drug B is prepared according to the method disclosed in WO2007085188A;

Mice: Strain: BALB/c nude mice; Week age and weight: 6-8 weeks of age, weighing 18-22 grams; Gender: Female; Quantity: 42; Supplier: Shanghai Xipuer-Bikai Laboratory Animal Co., Ltd. the company.

Cell source: xxT47D tumor cells were isolated and established cell lines in vitro from xenograft tumors constructed by parental T47D (ATCC, HTB-133) tumor cells.

2. Experimental methods and procedures

1) Establishment of xxT47D breast cancer model

xxT47D tumor cells are established by isolating xenograft tumors constructed from parental T47D tumor cells in vitro, and the establishment is completed by performing the same process twice. xxT47D tumor cells were adhered to the wall in vitro, and the culture conditions were RPMI 1640 medium with 10% fetal bovine serum, 100U/ml penicillin and 100μg/ml streptomycin, and cultured at 37°C with 5% CO ₂ . Use pancreatin-EDTA for routine digestion and passage twice a week. When the cell saturation is 80%-90%, the cells are collected, counted, and seeded.

2) Tumor cell inoculation

Estrogen tablets (0.18mg/tablet) were subcutaneously inoculated on the left back of each mouse. Three days later, 0.2mL (10×10e6cells+Matrigel, volume ratio 1:1) xxT47D cells were subcutaneously inoculated into each mouse. On the right back of the mouse, when the average tumor volume reached 173mm ³ , the drugs were administered in groups according to the experimental design (Table 1).

Table 1. Grouping of experimental animals and dosage regimen

Note: N: Number of mice in each group; Dosing volume: 10μl/g based on mouse body weight. If the weight loss exceeds 15%, the dosage regimen should be adjusted accordingly, (Vehicle A+Vehicle B) is the solvent group.

3) Test drug configuration

Table 2. Test drug configuration

4) The experimental index is to investigate whether the tumor growth is inhibited, delayed or cured. The tumor diameter was measured with vernier calipers twice a week. The calculation formula of tumor volume is: V=0.5a×b ² , a and b represent the long diameter and short diameter of the tumor, respectively.

The anti-tumor efficacy of the compound is evaluated by TGI (%) or relative tumor growth rate T/C (%). TGI (%) reflects the tumor growth inhibition rate. Calculation of TGI(%): TGI(%)=[(1-(Average tumor volume at the end of a certain treatment group-average tumor volume at the beginning of the treatment group))/(Average tumor at the end of treatment in the solvent control group Volume-The average tumor volume at the start of treatment in the solvent control group)]×100%

After the experiment is over, the tumor weight will be detected, and the percentage of T/C weight will be calculated. Tweight and Cweight represent the tumor weights of the administration group and the vehicle control group, respectively.

Statistical analysis, including the mean and standard error (SEM) of the tumor volume at each time point in each group. The treatment group showed the best treatment effect on the 21st day after the administration at the end of the trial, so statistical analysis was performed based on this data to evaluate the difference between the groups. The comparison between the two groups is analyzed by T-test, and the comparison between three or more groups is analyzed by one-way ANOVA. If the F value is significantly different, the Games-Howell method is used to test. If there is no significant difference in F value, the Dunnet (2-sided) method is used for analysis. Use SPSS 17.0 for all data analysis. p<0.05 considered a significant difference.

3. Experimental results

1) Weight change

The effect of test substance treatment on the body weight of xxT47D tumor-bearing mice is shown in Figure 1 and Figure 2.

2) Changes in tumor volume

Table 3 shows the changes of tumor volume in each group after treatment with xxT47D tumor-bearing mice.

Table 3. Tumor volume at different time points in each group

Note: a. Mean ± SEM; b. Days after administration

3) Tumor growth curve

The growth curve of each group of tumors is shown in Figure 3.

4) Evaluation index of anti-tumor efficacy

Table 4. Antitumor efficacy evaluation of drug A and drug B on xxT47D xenograft tumor model (calculated based on tumor volume on the 21st day after administration)

Note: a. Mean±SEM. b. Tumor growth inhibition is calculated by T/C and TGI (TGI(%)=[1-(T ₂₁ -T ₀ )/(V ₂₁ -V ₀ )]×100). The cp value is calculated based on the tumor volume.

Table 5. Tumor weight analysis of drug A and drug B groups

Note: a. Mean ± SEM. b. Tumor growth inhibition is calculated by T/Cweight=Tweight/Cweight. c.p value is calculated based on tumor weight.

4. Experimental discussion

21 days after the start of administration, the average tumor volume of tumor-bearing mice in the solvent control group reached 1283 mm ³ , the average tumor volume of the test substance 25 mg/kg drug A and 10 mg/kg drug B group were 724 mm ³ and 311 mm ^{3 respectively} and the solvent control group Compared with significant tumor suppression effect (p value is 0.020 and <0.001, respectively). 10mg/kg drug B has the best anti-tumor effect, with TGI reaching 88%.

The average tumor volume of the 25mg/kg drug A combined with 10mg/kg drug B treatment group was 158mm ³ , which was significantly different compared with the solvent group (p<0.001). Compared with the respective single-agent groups, the combined group showed more Strong anti-tumor activity, and the difference is significant. Compared with the single drug, the p-values of drug A and drug B are 0.003 and 0.035, respectively. The tumor weight results (Table 5) are basically consistent with the tumor volume results.

In summary, drug A and drug B single drugs showed significant anti-tumor activity on the xxT47D human breast cancer xenograft tumor model at the dose of the test protocol. Compared with a single drug, the combined application of drug A and drug B can further enhance the anti-tumor effect.

Although the specific embodiments of the present invention are described above, those skilled in the art should understand that these are merely examples, and various changes or modifications can be made to these embodiments without departing from the principle and essence of the present invention. modify. Therefore, the protection scope of the present invention is defined by the appended claims.

Claims (12)

1. The use of a combination of a CDK4/6 inhibitor and a multi-target tyrosine kinase inhibitor in the preparation of a medicine for treating tumors.
2. The use according to claim 1, wherein the CDK4/6 inhibitor is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof,

   
3. The use according to claim 2, wherein the pharmaceutically acceptable salt of the compound represented by formula (I) is isethionate.
4. The use according to claim 1, wherein the multi-target tyrosine kinase inhibitor is a compound represented by formula (II) or a pharmaceutically acceptable salt thereof,

   
5. The use according to claim 4, wherein the compound represented by formula (II) or a pharmaceutically acceptable salt thereof is malate.
6. The use according to any one of claims 1-5, wherein the tumor is selected from sarcoma, lymphoma, lung cancer, bronchial cancer, prostate cancer, pancreatic cancer, gastrointestinal cancer, colon cancer, rectal cancer, colorectal adenoma, Thyroid cancer, liver cancer, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, adrenal gland cancer, gastric cancer, gastric tumor, glioma, glioblastoma, endometrial cancer, melanoma, kidney cancer, renal pelvis cancer, bladder cancer, Uterine body cancer, cervical cancer, vaginal cancer, ovarian cancer, multiple myeloma, esophageal cancer, leukemia, acute myeloid leukemia, chronic myeloid leukemia, lymphocytic leukemia, myelogenous leukemia, brain tumor, brain cancer, Oral and pharynx cancer, laryngeal cancer, small bowel cancer, non-Hodgkin's lymphoma, melanoma, colon chorioaldenoma, neoplasm, epithelial cancer, breast cancer, basal cell carcinoma, squamous cell carcinoma, actinic horn Metaplastic diseases, tumors, neck or head tumors, primary thrombocytosis, myeloid metaplastic myelofibrosis and macroglobulinemia, preferably breast cancer, hepatocellular carcinoma, colon cancer.
7. The use according to claim 6, wherein the breast cancer is hormone receptor positive breast cancer.
8. The use according to claim 6, wherein the dosage of the CDK4/6 inhibitor is selected from 1-500mg, preferably 50-200mg, more preferably 100-150mg, and the frequency of administration is once a day and twice a day. Preferably once a day.
9. The use according to claim 8, the dosage of the CDK4/6 inhibitor is 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, preferably 100mg, 125mg or 150mg, and the frequency of administration is once a day, twice a day Times, preferably once a day.
10. The use according to any one of claims 8-9, the dosage of the multi-target tyrosine kinase inhibition is 0.1-1000 mg or 0.1-10 mg/kg, and the frequency of administration is once a day and twice a day. Twice or three times a day, preferably once a day.
11. The use according to claim 10, wherein the dosage of the multi-target tyrosine kinase inhibition is selected from 15mg, 20mg, 25mg, and the frequency of administration is once a day, twice a day or three times a day, Preferably once a day.
12. A pharmaceutical composition comprising the CDK4/6 inhibitor according to any one of claims 1-11, a multi-target tyrosine kinase inhibitor, and one or more pharmaceutically acceptable excipients, diluents or Carrier.

Images